These four names provide a way to stay in the game -- from a safe distance -- and grow some green.
Cannabis investors have been sorely disappointed in the stock's performance.
Cannabis player came under scrutiny for number of store licenses in state.
U.S. cannabis sales jumped 23% in 2019, according to a recent report.
Prices continue to fall ahead of National Hemp Day.
There is nothing in small-caps to suggest that they are as frothy as the big-caps.
Look for Aphria to remain a major player in the industry.
As vape illnesses have dropped, it seems consumers are drifting back to making vape purchases.
Buyers of the beer and wine seller's shares have become more aggressive.
While 2019 was a decidedly bad year for cannabis stocks, 2020 could be looking more positive.
The U.S. markets are why cannabis stock valuations will improve.
But its investors may still feel burnt from the diluted shares; meanwhile, the new year could be when several cannabis stocks go to pot.
Firm sees shares dip after accusations by short-seller Grizzly Research surface in business media.
If you want to find cheap stocks with great potential to rebound in 2020, the best place to look is marijuana names.
As the year winds down, many frothed up stocks of cannabis companies dipped -- here's a way to roll up your investments going into the new year.
The cannabis company just brought on STZ executive as new CEO, and this move is likely lining up bigger things to come as sector shakes out.
The 'toy' company is just too cheap and attractive, right now; plus, those pot stocks are looking to be in a funk.
State becomes 10th to sell recreational marijuana.
Morningstar Magazine offers insight into future growth potential for cannabis industry and stocks.
A look at what the weekly charts of three big cannabis names are saying.
These companies didn't make it any easier on themselves this year.
Prices are dropping faster than Myles Garrett from fantasy football rosters just as costs are about to rise.
CGC reported a wider than expected loss that included a slew of write-downs leading some to conclude this a kitchen sink quarter.
Cannabis consumers have become very cautious as to the products they purchase.
Canaccord cuts price target for the firm that's set to release earnings Nov. 20.
Joint venture partner Emerald Health appears to be struggling.
These 'bearish bets' are showing both technical and quantitative deterioration.
The point here is an exit doesn't have to be permanent. It is part of a risk management strategy, not an absolute end of a trade.
I thought the sector might have been bottoming out, but it's not.
This group appears oversold and downgrades of the big cannabis names may trigger a "buy the bad news" reaction.